All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Decoding the historical tale: COVID-19 impact on haematological malignancy patients: EPICOVIDEHA insights from 2020 to 2022

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013648" target="_blank" >RIV/00023736:_____/24:00013648 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/24:00137430 RIV/65269705:_____/24:00080457 RIV/00179906:_____/24:10484297 RIV/00064173:_____/24:43927649 and 2 more

  • Result on the web

    <a href="https://doi.org/10.1016/j.eclinm.2024.102553" target="_blank" >https://doi.org/10.1016/j.eclinm.2024.102553</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.eclinm.2024.102553" target="_blank" >10.1016/j.eclinm.2024.102553</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Decoding the historical tale: COVID-19 impact on haematological malignancy patients: EPICOVIDEHA insights from 2020 to 2022

  • Original language description

    The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced. The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020–2022). Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-19 cases.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2024

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    EClinical medicine

  • ISSN

    2589-5370

  • e-ISSN

  • Volume of the periodical

    71

  • Issue of the periodical within the volume

    May

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    20

  • Pages from-to

    "art. no. 102553"

  • UT code for WoS article

    001311054400001

  • EID of the result in the Scopus database

    2-s2.0-85188194524